Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Mythili Koneru, MD, PhD, as Chief Medical Officer. Dr. Koneru will lead clinical development, medical strategy, and regulatory engagement as the company advances its pipeline, including first-in-class oral small molecule mRNA degrader, REM-422, through clinical development and regulatory milestones. “Mythili’s deep experience advancing novel therapies in oncology through rigorous translational science and disciplined clinical execution will be critical as we advance REM-422 and our broader pipeline,” said Pete Smith, PhD, Co-Founder and Chief Executive Officer of Remix. “We are excited to have her lead our development group as we work to translate the promise of our RNA-targeting platform into meaningful medicines for pati
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) [Yahoo! Finance]Yahoo! Finance
- Why The Legend Biotech LEGN Story Is Shifting As Carvykti And Competition Reframe Expectations [Yahoo! Finance]Yahoo! Finance
- Legend Biotech (NASDAQ:LEGN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $75.00 price target on the stock.MarketBeat
LEGN
Sec Filings
- 1/14/26 - Form 6-K
- 1/12/26 - Form 6-K
- 12/29/25 - Form 144
- LEGN's page on the SEC website